Drugs (Pharmaceuticals) – Page 4

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.

By Teddy Rosenbluth

Centers for Medicare and Medicaid Services Drugs (Pharmaceuticals) Health Insurance and Managed Care Inflation Reduction Act of 2022 Medicare Medicare Advantage Presidential Election of 2024 Prices (Fares, Fees and Rates) United States Politics and Government

Biden Officials Stave Off Sticker Shock on Medicare Drug Premiums

Federal regulators spent billions of dollars to avoid a spike in costs for older Americans that could have been politically damaging to the presidential campaign of Vice President Kamala Harris.

By Rebecca Robbins and Reed Abelson

Bristol Myers Squibb Company Clinical Trials Dopamine Drugs (Pharmaceuticals) Food and Drug Administration Karuna Therapeutics Inc Psychiatry and Psychiatrists Psychology and Psychologists Regulation and Deregulation of Industry Research Schizophrenia Therapy and Rehabilitation Weight

F.D.A. Approves a New Antipsychotic Drug

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

By Ellen Barry and Christina Jewett

Antibiotics Deaths (Fatalities) Developing Countries Drug Resistance (Microbial) Drugs (Pharmaceuticals) General Assembly (UN) Infections Lancet, The (Journal) Medicine and Health Poverty Shortages

The Global Threat of Antibiotic Resistance

International health experts have begun to shift their focus to try to provide access to basic drugs in countries where preventable deaths from infections occur too frequently.

By Andrew Jacobs

mosaec